Skip to content
Screener

Denali Therapeutics Inc. DNLI Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$0.010.0%

Other financials

Income statement

See full
Revenue$3.6M
Gross profit$3.5M
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 10)
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 159,755,526 shares and 156,182,177 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1,9241,888
Additional paid-in capital3,142,7473,062,715
Accumulated other comprehensive income (loss)(1,969)682
Accumulated deficit(2,307,524)(2,051,524)
Total stockholders' equity835,1781,013,761

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s common stock par value per share?
Denali Therapeutics Inc. (DNLI) reported common stock par value per share of $0.01 in Q2 2026.
How has Denali Therapeutics Inc.'s common stock par value per share changed year-over-year?
Denali Therapeutics Inc.'s common stock par value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
What is the long-term trend for Denali Therapeutics Inc.'s common stock par value per share?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.

Ask your AI about Denali Therapeutics Inc.'s common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude